simvastatin has been researched along with Diabetes Mellitus, Type 2 in 255 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (10.59) | 18.2507 |
| 2000's | 108 (42.35) | 29.6817 |
| 2010's | 102 (40.00) | 24.3611 |
| 2020's | 18 (7.06) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Aerooj, H; Majeed Khan, H; Nawaz, H; Sharif, A | 1 |
| Bjourson, AJ; English, AR; Horigan, G; Kelly, C; McClean, PL; McGuigan, DH; O'Kane, M; Prasad, B; Shukla, P | 1 |
| Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S | 1 |
| Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F | 1 |
| Li, L; Sun, Q; Zhou, Q | 1 |
| Ho, LT; Hwu, CM; Lee, IT; Sheu, WH; Wu, TH | 1 |
| Chen, J; Li, P; Liu, H; Meng, L; Wang, K; Wang, L; Yang, H; Zheng, Z; Zhu, L | 1 |
| da Rocha, IG; da Silva Júnior, JG; da Silva Neto, JC; de Araújo, HDA; de Menezes Lima, VL; de Oliveira Assis, SP; Oliveira, RN | 1 |
| AmeliMojarad, M; Pourmadian, A | 1 |
| Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V | 1 |
| Bora, V; Gajjar, S; Patel, BM | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 2 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Battaglia, M; Benincasa, G; Bignucolo, A; Comello, F; De Lucia, D; De Lucia, V; Di Francia, R; Grillo, MR; Leonardi, G; Licito, A; Marotta, G; Mentone, L | 1 |
| Bell, KJL; Hayen, A; Zhu, L | 1 |
| Kopylov, VY | 1 |
| Adler, GK; Bayomy, O; Di Carli, MF; Garg, R; Jerosch-Herold, M; Kotin, AR; Kwong, RY; Nijmeijer, S; Rao, AD; Reiber, B; Vaidya, A | 1 |
| Dworacka, M; Dworacki, G; Frycz, BA; Iskakova, S; Jagodziński, PP; Stelmaszyk, A; Wesołowska, A; Zharmakhanova, G | 1 |
| Bumbasirevic, V; Ciric, D; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V | 1 |
| Attia, MS; Bahammam, MA | 1 |
| Buranasupkajorn, P; Buse, JB; Doria, A; Gao, H; Gerstein, HC; Hastings, T; Kraft, P; Marcovina, SM; Mendonca, C; Morieri, ML; Motsinger-Reif, AA; Mychaleckyj, JC; Parè, G; Pigeyre, M; Rotroff, DM; Shah, HS; Sigal, RJ; Sjaarda, J; Wagner, MJ | 1 |
| Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL | 1 |
| Ambrosius, WT; Beddhu, S; Boucher, R; Bress, AP; Chertow, GM; Cheung, AK; Cushman, WC; Cutler, J; Fine, L; Greene, T; Kimmel, PL; Kramer, H; Lewis, CE; Oparil, S; Rahman, M; Wei, G; Whelton, PK; Zhang, C | 1 |
| Aliko, A; Bielecka, E; Binder, V; Delaleu, N; Hellvard, A; Kamińska, M; Kantyka, T; Marczyk, A; Mydel, P; Potempa, J | 1 |
| Barreto, J; Breder, I; Carvalho, LSF; Coelho Filho, OR; Coelho, OR; Cunha, J; Martins, NS; Matos-Souza, JR; Mello, DSS; Munhoz, DB; Nadruz, W; Silva, JCQE; Soares, AAS; Sposito, AC | 1 |
| Bogman, K; Brumm, J; Giraudon, M; Hofmann, C; Mangold, B; Niggli, M; Sauter, A; Schmitt, C; Sturm, S; Sturm-Pellanda, C | 1 |
| Bahrey, D; Demoz, GT; Hagazy, K; Kasahun, GG; Kinfe, DG; Niriayo, YL; Tasew, H; Wahdey, S | 1 |
| Chen, X; Liu, S; Liu, Y; Song, Y; Yang, X; Zhou, Y | 1 |
| Cai, L; Sun, W; Xu, J; Xu, W; Yao, H; Zhou, Q | 1 |
| Kennedy, RL; Malabu, UH; Vangaveti, V | 1 |
| Koh, KK | 1 |
| Boekholdt, SM; Pedersen, TR; Waters, DD | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Farkouh, ME; Sethi, SS | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Cirillo, G; Tedeschi, G; Tessitore, A; Todisco, V | 1 |
| Hirano, T; Iijima, R; Inazawa, T; Kawamura, M; Kitazawa, T; Kohro, T; Mori, Y; Sakamoto, K; Shiba, T; Tagami, M; Tanaka, A; Yamazaki, T | 1 |
| Cai, L; Liu, G; Tan, Y; Xu, J; Zhou, Q | 1 |
| Demaine, AG; Hodgkinson, AD; Millward, BA; Shaw, NA; Yang, B | 1 |
| Byington, RP; Crouse, JR; Elam, MB; Force, RW; Ginsberg, HN; Ismail-Beigi, F; Leiter, LA; Linz, PE; Lovato, LC; O'Connor, PJ; Papademetriou, V; Simmons, DL; Weiss, D | 1 |
| Annema, W; de Boer, JF; Dullaart, RP; Tietge, UJ; Triolo, M | 1 |
| Loukovaara, S; Sahanne, S; Tuuminen, R | 1 |
| Golden, SH; Joseph, JJ | 1 |
| Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 4 |
| Chang, YH; Lee, YJ; Lin, KD; Shin, SJ | 1 |
| Hu, MY; Jia, LL; Li, F; Liu, C; Liu, L; Liu, XD; Wang, DW; Wu, J; Xu, D; Zhang, J; Zhang, M; Zhong, ZY | 1 |
| Ciriacks, K; Coly, G; Kidambi, S; Krishnaswami, S; Patel, SB | 1 |
| Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M | 1 |
| Farnier, M | 1 |
| Adams, CM; Fink, BD; Fox, DK; Herlein, JA; Sivitz, WI; Suneja, M | 1 |
| Kabbara, WK; Ramadan, WH | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Bekmukhambetov, Y; Dworacka, M; Dworacki, G; Iskakova, S; Zharmakhanova, G | 1 |
| Gdula-Dymek, A; Krysiak, R; Marek, B; Okopień, B | 2 |
| Boldrin, M; Georgy, A; Liang, Z; Zhai, S; Zhi, J | 1 |
| Amigó, N; Blanco Vaca, F; Correig, X; Escolà-Gil, JC; Heras, M; Mallol, R; Martínez-Hervás, S; Masana, L; Plana, N; Yanes, Ó | 1 |
| Ardanaz, E; Arriola, L; Balkau, B; Barroso, I; Boeing, H; Burgess, S; Deloukas, P; Forouhi, NG; Franks, PW; Grioni, S; Kaaks, R; Key, TJ; Langenberg, C; Lotta, LA; Luan, J; McCarthy, MI; Navarro, C; Nilsson, PM; O'Rahilly, S; Overvad, K; Palli, D; Panico, S; Perry, JRB; Quirós, JR; Riboli, E; Rolandsson, O; Sacerdote, C; Salamanca, EC; Sattar, N; Savage, DB; Scott, RA; Sharp, SJ; Slimani, N; Spijkerman, AM; Stewart, ID; Tjonneland, A; Tumino, R; van der A, DL; van der Schouw, YT; Wareham, NJ; Willems, SM | 1 |
| Kowluru, A; Sidarala, V | 1 |
| Aggarwal, AN; Badal, D; Bhansali, A; Bhat, OM; Rastogi, A; Singla, M | 1 |
| Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Corretti, V; Ferrannini, E; Madec, S; Santini, E; Solini, A | 1 |
| Anderwald, C; Bayerle-Eder, M; Brehm, A; Esterbauer, H; Hofer, A; Krssak, M; Nowotny, P; Pfeiler, G; Roden, M; Szendroedi, J; Waldhäusl, W | 1 |
| Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD | 1 |
| Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M | 1 |
| Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K | 1 |
| de Vries, R; Dullaart, RP; Sluiter, WJ; van Tol, A; Voorbij, HA | 1 |
| Heljić, B; Kulić, M; Velija-Asimi, Z | 1 |
| De Flines, J; Jandrain, BJ; Radermecker, RP; Scheen, AJ | 1 |
| Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Wang, XM | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Böhm, F; Kalani, M; Pernow, J; Rydén, L; Settergren, M | 1 |
| Galvano, F; Li Volti, G; Malaguarnera, M; Motta, M; Vacante, M | 1 |
| Antic, T; Avitabile, T; Galvano, F; Li Volti, G; Malaguarnera, M; Vacante, M | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Franzetti, IG; Gadaleta, G; Piccinni, MN; Ragonesi, PD; Scalise, F | 1 |
| Bi, S; Li, J; Li, YB; Liu, GD; Liu, XM; Su, Y; Sun, YM; Xu, Y | 1 |
| Balwanz, CR; Grimm, PR; Padanilam, BJ; Sansom, SC; Settles, DC; Wei, P | 1 |
| Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Galli, A; Lauro, D; Lombardo, MF; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Kasalová, Z; Kvasnicka, J; Mazoch, J; Prázný, M; Skrha, J | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS | 1 |
| Nilsson, PM | 1 |
| Bigger, JT; Buse, JB; Byington, RP; Crouse, JR; Cushman, WC; Elam, MB; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Ismail-Beigi, F; Leiter, LA; Linz, P; Lovato, LC; Probstfield, J; Simons-Morton, DG | 1 |
| Charles, MA; Ishida, B; Kane, JP; Malloy, MJ; Pan, J; Shilian, P; Wu, X | 1 |
| Gong, DW; Hu, Y; Pan, J; Ryan, K; Shuldiner, AR; Tong, G; Xu, W; Yang, R; Zhu, D | 1 |
| Biancini, GB; Dal Vesco, AM; Manfredini, V; Peralba, Mdo C; Vanzin, CS; Vargas, CR; Wayhs, CA | 1 |
| Bardini, G; Giorda, CB; Le Grazie, C; Pontiroli, AE; Rotella, CM | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Belviso, A; Bossi, AC; Cattaneo, D; Diadei, O; Ene-Iordache, B; Ferrari, S; Iliev, I; Parvanova, A; Remuzzi, G; Rota, S; Ruggenenti, P; Trevisan, R | 1 |
| Klein, BE | 1 |
| Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U | 1 |
| Biancini, GB; Biasi, L; Cipriani, F; Dal Vesco, AM; Deon, M; Manfredini, V; Peralba, Mdo C; Treméa, R; Vanzin, CS; Vargas, CR; Wajner, M | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Gensini, GF; Hanson, ME; Le Grazie, C; Rotella, CM; Zaninelli, A | 1 |
| Pérez, A | 1 |
| Drexel, H; Rein, P; Saely, CH | 1 |
| Chen, L; Tonkin, AM | 1 |
| Ahnström, J; Dahlbäck, B; de Vries, R; Dikkeschei, BD; Dullaart, RP; Kappelle, PJ; Nielsen, LB; Sluiter, WJ; van Tol, A; Wolffenbuttel, BH | 1 |
| Perkins, WJ | 1 |
| Katsiki, N; Mikhailidis, DP; Sarigianni, M | 1 |
| Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE | 1 |
| Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopien, B | 1 |
| Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Balink, H; de Graaf, W; Grond, J; Hemmelder, MH | 1 |
| Dodson, PM; Wright, AD | 1 |
| Annuzzi, G; Bozzetto, L; Cipriano, P; Corte, GD; Mangione, A; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Ginsberg, HN | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Hoffmann, MM; Jacob, S; Konrad, T; Müller-Schewe, T; Winkler, K | 1 |
| Teramoto, T | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
| Martin, PY; Saudan, P | 1 |
| Bajaj, P; Kumari, M; Pradeep, AR; Rao, NS | 1 |
| Bierhaus, A; Djuric, Z; Fleming, T; Grafe, IA; Groener, JB; Metzner, C; Nawroth, PP; Reismann, P; Rudofsky, G | 1 |
| Andreadi, K; Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Federici, M; Lauro, D; Lombardo, MF; Quon, MJ; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Almquist, T; Farndale, RW; Hjemdahl, P; Jacobson, SH; Lins, PE | 1 |
| Chowdhury, TA; Lasker, SS | 1 |
| Constantinides, A; de Vries, R; Dullaart, RP; Gautier, T; Lagrost, L; Tselepis, AD; van Leeuwen, JJ; van Pelt, LJ | 1 |
| Ceska, R; Marinov, I; Skrha, J; Stulc, T | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Dallinga-Thie, GM; de Vries, R; Dikkeschei, BD; Dullaart, RP; Sluiter, WJ; van Tol, A | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Chowdbury, TA; Lasker, SS | 1 |
| Bais, B; Ceriello, A; Da Ros, R; Motz, E; Piconi, L; Quagliaro, L; Taboga, C; Tonutti, L | 1 |
| Liu, H; Wu, G; Ye, X; Zhu, Y | 1 |
| Frei, B; Higdon, JV | 1 |
| Faust, M | 1 |
| Brizzi, P; Maioli, M; Melis, MG; Secchi, G; Tonolo, G | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Yokota, C | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Mikhail, N | 1 |
| Chan, CC; Chew, EY; Cusick, M; Ferris, FL; Kruth, HS; Murphy, RP | 1 |
| Durazo-Arvizu, R; Lopes-Virella, MF; Mironova, M; Stephan, E; Virella, G | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Kipnes, MS; Lewin, AJ; Maccubbin, DL; Meneghini, LF; Mitchel, YB; Perevozskaya, IT; Plotkin, DJ; Shah, S; Tobert, JA | 1 |
| Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Battisti, WP; Borisute, H; Dobs, A; Miller, M; Palmisano, J; Yuan, Z | 1 |
| Gregoriades, M; Petrou, M; Vassiliou, V | 1 |
| Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT | 1 |
| Gaudiani, LM; Lewin, A; Meneghini, L; Mitchel, Y; Perevozskaya, I; Plotkin, D; Shah, S | 1 |
| Han, M; Li, JB; Liu, KZ; Lu, HL; Wen, JK | 1 |
| Deeg, MA; Jacob, S; Jacob, SS; Williams, C | 1 |
| Citkowitz, E; Michelena, HI; Osorio, LA | 1 |
| Kawamori, R; Miwa, S; Nishiyama, K; Omura, C; Onuma, T; Takayanagi, N; Tanaka, Y; Watada, H | 1 |
| Ahn, JY; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Quon, MJ; Shin, EK | 1 |
| Beishuizen, ED; Huisman, MV; Jukema, JW; Meinders, AE; Tamsma, JT; van de Ree, MA; van der Vijver, JC | 1 |
| Goto, R; Higashi, K; Ishii, N; Itai, K; Kobori, S; Takahashi, T | 1 |
| Amir, K; Ashraf, R; Shaikh, AR | 1 |
| Dharmalingam, S; Erickson-Nesmith, S; Fenton, JW; Ludwig, S; Ma, GM; Ofosu, FA; Ren, S; Shen, GX; van Mierlo, G; Velthuis, HT; Zhao, R; Zhu, F | 1 |
| Harris, WS; Isley, WL; Miles, JM; Patterson, BW | 1 |
| Capurso, A; Capurso, C; Capurso, SA; Colacicco, AM; D'Introno, A; Fontana, C; Gadaleta, AM; Koverech, A; Panza, F; Solfrizzi, V; Torres, F | 1 |
| Battisti, WP; Dobs, A; Miller, M; Palmisano, J; Yuan, Z | 1 |
| Gao, F; Hu, XF | 1 |
| Abaterusso, C; Abhyankar, A; Brocco, E; Carraro, A; Faedda, R; Luthman, H; Morgia, G; Nosadini, R; Satta, A; Tonolo, G; Velussi, M | 1 |
| Harris, WS; Isley, WL; Miles, JM | 1 |
| Itakura, H; Kita, T; Mabuchi, H; Matsuzaki, M; Matsuzawa, Y; Nakaya, N; Oikawa, S; Saito, Y; Sasaki, J; Shimamoto, K | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD | 1 |
| Harris, WS; Isley, WL; Park, Y | 1 |
| Ahn, JY; Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Bei, R; Chiarelli, F; Cipollone, F; Cuccurullo, C; Cuccurullo, F; De Cesare, D; Di Francesco, A; Fazia, ML; Iezzi, A; Mezzetti, A; Muraro, R; Schmidt, AM; Spigonardo, F; Ucchino, S | 1 |
| Canatar, T; Demircan, S; Ermiş, N; Erol, T; Katircibaşi, T; Koçum, T; Müderrisoğlu, H; Sezgin, AT; Sipahi, I; Tekin, A; Tekin, G; Unsal, A; Yiğit, F | 1 |
| Gonokhova, LG | 1 |
| Capell, WH; Eckel, RH; Gerard, LA; Hernandez, TL; Wolfe, P | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Chan, YH; Lim, SC; Sum, CF; Tavintharan, S | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Hattori, H; Higuchi, S; Iida, M; Iwase, M; Ohdo, S; Sasaki, N; Sonoki, K | 1 |
| McMahon, DE | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Dollerup, J; Gormsen, LC; Mogensen, CE; Nellemann, B; Nielsen, S; Rasmussen, LM; Schmitz, O | 1 |
| An, CY; Gao, YY; Liu, XM; Sun, YM; Ying, S | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Guan, JZ; Matsui, J; Matsuki, K; Murakami, H; Suda, T; Tamasawa, N; Tanabe, J; Yamashita, M | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD | 1 |
| Doney, AS; Donnan, PT; Donnelly, LA; Lang, CC; Morris, AD; Palmer, CN; Whitley, AL | 1 |
| Ames, PR | 1 |
| Kamata, K; Kobayashi, T; Matsumoto, T; Takenouchi, Y | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
| Müderrisoğlu, H; Sezgin, AT; Tekin, A; Tekin, G | 1 |
| Iwasaki, T; Kato, S; Sasaki, H; Tada, N | 1 |
| Appel, S; Hitzenberger, G; Kalafsky, G; Kallay, Z; Kutz, K; Rüfenacht, T; Tetzloff, W | 1 |
| Amano, M; Ino, T; Kasuga, M; Kazumi, T; Matsuba, K; Ohki, A; Yoshino, G | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Daubresse, JC; Machowski, R; Pulinx, E | 1 |
| Alberti, KG; Evans, K; Farrer, M; Kesteven, P; Laker, MF; Neil, HA; Winocour, PH | 1 |
| Camarda, G | 1 |
| Foresta, C; Guarneri, G; Lavagnini, T; Padovan, D; Rossato, M | 1 |
| Alberti, KG; Klausen, IC; Mogensen, CE; Møller, N; Nielsen, S; Pørksen, N; Schmitz, O | 1 |
| Alemanno, N; Cassader, M; Gambino, R; Pagano, G; Ruiu, G; Veglia, F | 1 |
| Miura, Y; Nakano, H; Nishimura, M; Sakai, O; Shibasaki, T; Suzuki, S; Tuchida, H; Wakabayashi, Y; Yamada, K | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Atzeni, MM; Brizzi, P; Calvia, P; Ciccarese, M; Maioli, M; Melis, MG; Puddu, L; Secchi, G; Tonolo, G | 1 |
| Garg, A | 1 |
| Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| Hall, RR | 1 |
| Collins, P; Deegan, P; Johnson, A; Owens, D; Tomkin, GH | 1 |
| Hayakawa, T; Inada, M; Miyake, Y; Nishikawa, M; Omoto, S; Shimizu, H; Shouzu, A; Yonemoto, T | 1 |
| Chen, YT; Juang, BL; Lee, WJ; Sheu, WH | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Chen, HS; Ho, LT; Hsiao, LC; Hwu, CM; Kwok, CF; Lee, SH; Lin, SH; Shih, KC | 1 |
| Taskinen, MR | 1 |
| Ito, MK; Lin, JC | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Gavish, D; Leibovitz, E; Rubinstein, A; Shapira, I | 1 |
| Bays, H; Davidson, M; Dujovne, C; Korenman, S; Mercuri, M; Plotkin, D; Stein, E; Stepanavage, M | 1 |
| Angius, MF; Brizzi, P; Carboni, A; Cherchi, GM; Ciccarese, M; Formato, M; Maioli, M; Melis, MG; Tonolo, G | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Chen, YT; Jeng, CY; Lee, WJ; Lin, SY; Pei, D; Sheu, WH | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Caldwell, SH; Hespenheide, EE; von Borstel, RW | 1 |
| Farvid, AR; Gibson, MF; Hoffmeyer, MR; Jones, SP; Lefer, AM; Lefer, DJ; Scalia, R; Sharp, BR | 1 |
| Chen, YT; Lee, WJ; Sheu, WH | 1 |
| Haenni, A; Lithell, H; Ohrvall, M | 1 |
| Blauw, GJ; de Man, FH; Huisman, MV; Meinders, AE; van de Ree, MA; van der Vijver, JC | 1 |
| Adachi, M; Hirano, T; Katagiri, T; Koba, S; Sakai, K; Sakaue, T; Yoshino, G | 1 |
| Kumar, A; Misra, A; Pandey, RM; Sen, K | 1 |
| Goyal, RK; Udawat, H | 1 |
| Demant, T | 1 |
| Brambilla, C; Brambilla, E; Devouassoux, G; Lantuejoul, S | 1 |
| Geiss, HC; Parhofer, KG; Schwandt, P | 1 |
| Basit, A; Hakeem, R; Hydrie, MZ; Rehman, H | 1 |
| Bonnici, F; Fourie, J; Kotze, TJ; Lourens, W; Omar, MA; Stander, I; Steyn, K; van Lathem, J; Vermaak, WJ; Weich, HF | 1 |
| Beghè, F; Frustaci, G; Notarangelo, R; Pentimone, F; Pipicelli, G | 1 |
| D'Onofrio, F; De Riu, S; Gambardella, A; Paolisso, G; Sgambato, S; Varricchio, M; Verza, M | 1 |
14 review(s) available for simvastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Rosuvastatin Calcium; Simvastatin | 2023 |
Type 2 diabetes and cardiovascular disease: what next?
Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Obesity; Risk Factors; Risk Reduction Behavior; Simvastatin; Sleep Wake Disorders; Socioeconomic Factors; Stress, Psychological | 2014 |
Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Triglycerides | 2014 |
Ezetimibe/statin combination therapy to treat patients with type 2 diabetes.
Topics: Azetidines; Biomarkers; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Simvastatin; Treatment Outcome | 2015 |
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain | 2015 |
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Genetic Association Studies; Genetic Variation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Odds Ratio; Polymorphism, Genetic; Proprotein Convertase 9; Receptors, LDL; Risk; Simvastatin | 2016 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Practice Guidelines as Topic; Simvastatin | 2009 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Lipids; Middle Aged; Simvastatin | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
[Prevention of cardiovascular disease in type 2 diabetic patients].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Risk; Risk Factors; Simvastatin | 2003 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Treatment of diabetic dyslipidemia.
Topics: Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Eicosapentaenoic Acid; Estrogen Replacement Therapy; Exercise; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipoproteins, VLDL; Postmenopause; Risk Factors; Simvastatin; Weight Gain | 1998 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Risk Factors; Simvastatin | 1999 |
125 trial(s) available for simvastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Combined lipid goal attainment in patients with type 2 diabetes and dyslipidemia: A head-to-head comparative trial of statins.
Topics: Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2022 |
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2020 |
Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enalapril; Female; Humans; Male; Middle Aged; Pericardium; Plasminogen Activator Inhibitor 1; Risk Factors; Simvastatin | 2017 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fenofibrate; Genetic Association Studies; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Simvastatin | 2018 |
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Simvastatin; Time Factors | 2018 |
Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Male; Middle Aged; Prognosis; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome; United States | 2018 |
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Anticoagulants; Cardiotonic Agents; Case-Control Studies; Contraceptives, Oral; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Injections, Subcutaneous; Lisinopril; Male; Middle Aged; Peptides; Pharmaceutical Preparations; Simvastatin; Warfarin | 2019 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Sex Factors; Simvastatin | 2013 |
Analysis of serum and urinal copper and zinc in Chinese northeast population with the prediabetes or diabetes with and without complications.
Topics: Adolescent; Adult; Aged; Asian People; Child; China; Copper; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Prediabetic State; Simvastatin; Young Adult; Zinc | 2013 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome | 2014 |
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Topics: Anti-Inflammatory Agents; Antioxidants; Bezafibrate; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin | 2014 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Factors; Risk Reduction Behavior; Simvastatin; Stroke | 2014 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.
Topics: Aged; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Male; Middle Aged; Mitochondria, Muscle; Muscles; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Simvastatin; Ubiquinone | 2015 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzeneacetamides; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Enzyme Activators; Female; Glucokinase; Humans; Male; Middle Aged; Simvastatin | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Simvastatin | 2016 |
Vitamin D supplementation improves simvastatin-mediated decline in exercise performance: A randomized double-blind placebo-controlled study.
Topics: Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Exercise; Exercise Therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Myalgia; Oxygen Consumption; Simvastatin; Vitamin D; Vitamins | 2017 |
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
Topics: Albumins; Biomarkers; Blood Pressure; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.
Topics: Adult; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Liver; Magnetic Resonance Spectroscopy; Middle Aged; Placebos; Reference Values; Simvastatin | 2009 |
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; CD40 Ligand; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.
Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2009 |
Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Aryldialkylphosphatase; Bezafibrate; Carboxylic Ester Hydrolases; Case-Control Studies; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Male; Middle Aged; Simvastatin; Statistics as Topic | 2009 |
The statins in prevention of coronary heart diseases in type 2 diabetics.
Topics: C-Reactive Protein; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Risk Factors; Simvastatin | 2009 |
[Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Waist Circumference | 2009 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Foot; Forearm; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Simvastatin; Skin; Ultrasonography | 2009 |
Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin.
Topics: Adult; Aged; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Simvastatin | 2009 |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Topics: Apoprotein(a); Blood Glucose; Body Mass Index; Carnitine; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Simvastatin; Triglycerides | 2009 |
Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Prevalence; Simvastatin; Triglycerides | 2009 |
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Blood Glucose; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Necrosis Factor-alpha; Vasodilation | 2010 |
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Sex Factors; Simvastatin; Stroke; Treatment Failure; Triglycerides | 2010 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Simvastatin | 2011 |
Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis.
Topics: Adipokines; Adiponectin; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Serum Amyloid A Protein; Simvastatin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).
Topics: Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Middle Aged; Odds Ratio; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Young Adult | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2010 |
Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients.
Topics: Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Simvastatin | 2010 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Statistics as Topic | 2010 |
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2010 |
Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
Topics: Apolipoproteins; Apolipoproteins M; Bezafibrate; Blood Pressure; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipocalins; Male; Middle Aged; Placebos; Simvastatin | 2010 |
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Niacin; Simvastatin; Treatment Outcome | 2010 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Prospective Studies; Simvastatin; Vasodilator Agents | 2010 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome | 2011 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Centrifugation, Density Gradient; Cholesterol; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Fasting; Female; Humans; Lipoproteins, VLDL; Male; Middle Aged; Placebos; Postprandial Period; Simvastatin; Time Factors; Triglycerides | 2011 |
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Male; Placebo Effect; Simvastatin | 2011 |
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Centrifugation, Density Gradient; Diabetes Mellitus, Type 2; Down-Regulation; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial.
Topics: Adult; Alveolar Bone Loss; Chronic Periodontitis; Delayed-Action Preparations; Dental Scaling; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Longitudinal Studies; Male; Middle Aged; Osteogenesis; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Placebos; Root Planing; Simvastatin; Treatment Outcome | 2013 |
Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
Topics: Aged; Anti-Inflammatory Agents; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Combinations; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Inflammation Mediators; Interleukin-6; Male; Middle Aged; NF-kappa B; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.
Topics: Adiponectin; Biomarkers; Blood Glucose; Brachial Artery; C-Reactive Protein; Chi-Square Distribution; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Glucose Clamp Technique; Glycated Hemoglobin; Homeostasis; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Leptin; Lipids; Male; Middle Aged; Pyrimidines; Rome; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Blood Platelets; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Leukocytes; Lipids; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Prognosis; Risk Factors; Simvastatin; Young Adult | 2012 |
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Bezafibrate; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2012 |
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Topics: Adult; CD11a Antigen; CD18 Antigens; Cross-Over Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Integrin alpha4; Leukocytes; Lipids; Lipopolysaccharide Receptors; Male; Middle Aged; Simvastatin | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
Topics: Adult; Bezafibrate; Case-Control Studies; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Simvastatin | 2012 |
Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment.
Topics: Blood Glucose; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Female; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Oxidative Stress; Postprandial Period; Risk Factors; Simvastatin; Triglycerides; Tyrosine; Vasodilation | 2002 |
[The effects of tablet tongmaijiangzhi on hyperlipidemia and nitric oxide of patients with non-insulin-dependent diabetes mellitus].
Topics: Aged; Apolipoproteins; Blood Viscosity; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Nitric Oxide; Phytotherapy; Simvastatin; Tablets; Triglycerides | 2002 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pioglitazone; Rosiglitazone; Simvastatin; Thiazolidinediones | 2004 |
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Topics: Acetylglucosaminidase; Adult; Aged; alpha-Tocopherol; Ascorbic Acid; Cholesterol; Czech Republic; Diabetes Mellitus, Type 2; Drug Administration Schedule; E-Selectin; Endothelium; Female; Fenofibrate; Fibrinolysis; Glutathione; Humans; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Plasminogen Activator Inhibitor 1; Simvastatin; Superoxide Dismutase; Time Factors; Triglycerides; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2004 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Topics: Adult; C-Reactive Protein; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin; Treatment Outcome | 2004 |
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Statistics, Nonparametric; Thiazolidinediones | 2005 |
[Effects of Astragalus and saponins of Panax notoginseng on MMP-9 in patients with type 2 diabetic macroangiopathy].
Topics: Aged; Astragalus propinquus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Hypolipidemic Agents; Lipids; Male; Matrix Metalloproteinase 9; Middle Aged; Panax; Phytotherapy; Plants, Medicinal; Simvastatin | 2004 |
Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Topics: Adult; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Risk Factors; Simvastatin; Time Factors | 2005 |
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Malondialdehyde; Ramipril; Simvastatin; Vasodilation | 2005 |
The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.
Topics: Blood Flow Velocity; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyridines; Simvastatin; Ultrasonography | 2005 |
HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients.
Topics: Aged; Carotid Artery, Common; Cholesterol; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Tunica Intima; Tunica Media | 2005 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2005 |
Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Factor VII; Female; Fibrinolysis; Hemostasis; Humans; Lipids; Lipoproteins; Male; Middle Aged; Peptide Fragments; Plasminogen Activator Inhibitor 1; Prothrombin; Simvastatin; Tissue Plasminogen Activator | 2005 |
The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kinetics; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Obesity; Simvastatin; Single-Blind Method; Triglycerides | 2006 |
Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
Topics: Aged; Apolipoproteins B; Carnitine; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Italy; Lipoprotein(a); Male; Middle Aged; Simvastatin; Triglycerides | 2006 |
The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study.
Topics: Aged; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 2006 |
Effect of Taizhi'an capsule combined with Simvastatin on hyperlipidemia in diabetic patients.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Phytotherapy; Simvastatin; Triglycerides | 2006 |
Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albumins; Albuminuria; Anticholesteremic Agents; Cholestyramine Resin; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Kidney Glomerulus; Lipids; Male; Middle Aged; Podocytes; Proteins; RNA, Messenger; Simvastatin | 2006 |
The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitus.
Topics: Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Lipid Metabolism; Male; Middle Aged; Palmitates; Simvastatin; Single-Blind Method; Triglycerides | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Phospholipases A; Phospholipases A2; Simvastatin | 2006 |
The effect of high dose simvastatin on, platelet size in patients with, type 2 diabetes mellitus.
Topics: Blood Platelets; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Activation; Simvastatin; Single-Blind Method | 2006 |
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemostasis; Humans; Hypercholesterolemia; Male; Malondialdehyde; Middle Aged; Peptide Fragments; Prothrombin; Ramipril; Simvastatin; Thromboplastin | 2007 |
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Carotid Stenosis; Cells, Cultured; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Glucose; Glycation End Products, Advanced; Humans; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; NF-kappa B; Peroxidase; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Simvastatin | 2006 |
Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoprotegerin; Simvastatin | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Triglycerides | 2008 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Glyburide; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Lovastatin; Placebos; Simvastatin; Tolbutamide | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
Topics: Adult; Aged; Apolipoproteins B; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemostasis; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Female; Fructosamine; Glomerular Filtration Rate; Glycated Hemoglobin; Hexosamines; Humans; Hypercholesterolemia; Insulin; Kidney; Lovastatin; Male; Placebos; Simvastatin; Time Factors | 1993 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment.
Topics: Adult; Aged; Albuminuria; Anticholesteremic Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Simvastatin; Time Factors | 1997 |
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Finland; Gemfibrozil; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1998 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Chromatography, High Pressure Liquid; Coenzymes; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1999 |
Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypercholesterolemia; Reference Values; Simvastatin; Time Factors | 1999 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Hypercholesterolemia; Insulin; Male; Middle Aged; Placebos; Simvastatin | 1999 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Topics: Aged; Bezafibrate; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome | 2000 |
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Apolipoprotein A-I; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Triglycerides | 2000 |
Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.
Topics: Albuminuria; Anticholesteremic Agents; Apolipoproteins; Blood Pressure; Cholesterol, LDL; Cholestyramine Resin; Diabetes Mellitus, Type 2; Female; Glycosaminoglycans; Humans; Hypertension; Male; Middle Aged; Nitrates; Nitrites; Simvastatin | 2000 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period; Simvastatin; Triglycerides | 2001 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Disease Progression; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides; Vasodilation | 2001 |
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Magnesium; Simvastatin | 2001 |
Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelium, Vascular; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide Donors; Nitroprusside; Plethysmography; Regional Blood Flow; Serotonin; Simvastatin; Treatment Failure; Triglycerides; Vasodilator Agents | 2001 |
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia.
Topics: Blood Glucose; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fundus Oculi; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macular Degeneration; Photography; Placebos; Simvastatin; Visual Acuity | 2002 |
Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
117 other study(ies) available for simvastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |
Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination.
Topics: Animals; Cell Proliferation; Cell Survival; Chlorocebus aethiops; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; Drug Combinations; Drug Interactions; Drug Synergism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Mutagens; Simvastatin; Sitagliptin Phosphate; Vero Cells | 2021 |
Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.
Topics: Atorvastatin; Biological Specimen Banks; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Simvastatin; United Kingdom | 2022 |
Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Liberation; Emulsions; Nanoparticles; Particle Size; Rats; Simvastatin; Solubility; Streptozocin; Sulfonylurea Compounds | 2022 |
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose; Heart Failure; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Simvastatin | 2022 |
Effects of Ethanolic Extract of
Topics: Animals; Atorvastatin; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Schisandra; Simvastatin; Tandem Mass Spectrometry | 2022 |
Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Muscle, Skeletal; rab GTP-Binding Proteins; Simvastatin | 2022 |
Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance.
Topics: Animals; Carboxymethylcellulose Sodium; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Hormones; Hypolipidemic Agents; Insulin Resistance; Insulins; Lipoproteins, VLDL; Mice; Obesity; Phthalimides; Simvastatin; Transaminases; Triglycerides; Uric Acid | 2022 |
Simvastatin Therapy Increased miR-150-5p
Expression in the Patients with Type 2 Diabetes and COVID-19.
Topics: COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Lipids; MicroRNAs; Simvastatin | 2022 |
Effects of metformin and simvastatin treatment on ultrastructural features of liver macrophages in HFD mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Macrophages; Metformin; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Simvastatin | 2023 |
Repositioning of simvastatin for diabetic colon cancer: role of CDK4 inhibition and apoptosis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Diabetes Mellitus, Type 2; Drug Repositioning; Female; Humans; Male; Simvastatin | 2023 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; DNA; Female; Genotype; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Pain; Pain Measurement; Pharmacogenetics; Polymorphism, Single Nucleotide; Simvastatin; Sulfonylurea Compounds | 2020 |
Сhanges in the functional state of the epithelium of the proximal renal tubules in patients with the initial stage of chronic heart failure during simvastatin therapy.
Topics: Adult; Diabetes Mellitus, Type 2; Epithelium; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Tubules, Proximal; Middle Aged; Simvastatin; Young Adult | 2020 |
Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Rats; Rats, Wistar; Simvastatin | 2018 |
Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Myelin Sheath; Sciatic Nerve; Simvastatin | 2018 |
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-
Topics: Adult; Anticholesteremic Agents; Chronic Periodontitis; Diabetes Mellitus, Type 2; Female; Gingival Crevicular Fluid; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Simvastatin; Tumor Necrosis Factor-alpha | 2018 |
Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas gingivalis.
Topics: Biofilms; Diabetes Mellitus, Type 2; Fusobacterium nucleatum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Porphyromonas gingivalis; Simvastatin | 2019 |
Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven.
Topics: Anticholesteremic Agents; Blood Pressure; Brazil; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Male; Middle Aged; Prevalence; Risk Factors; Simvastatin; Triglycerides | 2019 |
Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ethiopia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2019 |
Effect of simvastatin on fracture healing of type 2 diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fracture Healing; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rats; Simvastatin | 2021 |
Associations of serum and urinary magnesium with the pre-diabetes, diabetes and diabetic complications in the Chinese Northeast population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Child; China; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Magnesium; Male; Middle Aged; Prediabetic State; Simvastatin; Young Adult | 2013 |
Statin treatment and diabetes.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
How to balance cardiometabolic benefits and risks of statins.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Reply: To PMID 23219296.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Clinical reasoning: a 62-year-old man with right wrist drop.
Topics: Blepharoptosis; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Evoked Potentials; Fingers; Functional Laterality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Movement Disorders; Myasthenia Gravis; Simvastatin; Wrist | 2013 |
Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro.
Topics: Albuminuria; Biomarkers; Cell Line, Transformed; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression Regulation; Glomerular Mesangium; Glucose; HEK293 Cells; Humans; Luciferases, Renilla; Promoter Regions, Genetic; Simvastatin; Transcription, Genetic; Transfection | 2013 |
Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment.
Topics: Adult; Aged; Angiopoietin-2; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Erythropoietin; Female; Humans; Hypolipidemic Agents; Macular Edema; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Prospective Studies; Simvastatin; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Vitrectomy; Vitreous Body | 2014 |
LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Monitoring; Half-Life; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunoassay; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2015 |
Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hepatocytes; Liver; Male; Microsomes, Liver; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; Simvastatin | 2014 |
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Body Mass Index; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Prospective Studies; Simvastatin; Waist Circumference | 2015 |
[Simvastatin's effect on insulin resistance in rats with diabetes mellitus].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Rats; Simvastatin | 2015 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Sex Factors; Simvastatin | 2015 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Indoles; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Middle Aged; Niacin; Simvastatin; Surface Properties; Triglycerides | 2016 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Retrospective Studies; Simvastatin; Treatment Outcome; Young Adult | 2016 |
Exposure to chronic hyperglycemic conditions results in Ras-related C3 botulinum toxin substrate 1 (Rac1)-mediated activation of p53 and ATM kinase in pancreatic β-cells.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Imidazoles; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Morpholines; p38 Mitogen-Activated Protein Kinases; Prenylation; Pyridines; Pyrones; Quinolines; rac1 GTP-Binding Protein; Rats; Simvastatin; Tumor Suppressor Protein p53 | 2017 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Estradiol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Simvastatin; Testosterone | 2009 |
The top 10 health stories of 2008.
Topics: Awareness; Azetidines; Blood Glucose; Brain Concussion; Delivery of Health Care; Diabetes Mellitus, Type 2; Diagnostic Imaging; Drug Combinations; Drugs, Generic; Ezetimibe, Simvastatin Drug Combination; Genetic Testing; Genomics; Health Care Reform; Humans; Hypertension; Periodicals as Topic; Simvastatin; Stem Cells; Warfare | 2008 |
[Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Decision Making; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Simvastatin | 2009 |
[Treatment of blood lipids abnormality in patients with diabetes mellitus].
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Triglycerides | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus.
Topics: Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glomerular Mesangium; Immunohistochemistry; Kidney Function Tests; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Organ Size; Podocytes; Probability; Random Allocation; Risk Factors; Severity of Illness Index; Simvastatin | 2009 |
Microvascular Reactivity and Endothelial Function in Type 2 Diabetic Patients with Hyperlipidemia Treated with Simvastatin: 3-year Follow-up.
Topics: Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Middle Aged; Simvastatin; Skin; Vasodilation | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
ACCORD and Risk-Factor Control in Type 2 Diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Risk Factors; Simvastatin | 2010 |
Apolipoprotein, C-reactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin.
Topics: Adult; Aged; Apolipoproteins; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Simvastatin | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Simvastatin | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Proportional Hazards Models; Risk; Simvastatin; Triglycerides | 2010 |
Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Lipids; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Simvastatin; Triglycerides | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenenti et al.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2010 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Young Adult | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Chester Disease; Gated Blood-Pool Imaging; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Knee Joint; Losartan; Male; Metformin; Positron-Emission Tomography; Prostatic Neoplasms; Simvastatin | 2011 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
[Nephrology].
Topics: Anticholesteremic Agents; Azathioprine; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Lupus Nephritis; Mycophenolic Acid; Nephrology; Renal Dialysis; Secondary Prevention; Simvastatin; Treatment Outcome | 2012 |
Myalgia while taking statins.
Topics: Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Drug Substitution; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Musculoskeletal Pain; Recurrence; Risk Factors; Simvastatin; Thyroid Function Tests | 2012 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
[Statin-induced myalgia].
Topics: Citrus paradisi; Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug Interactions; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Musculoskeletal Pain; Myositis; Quality of Life; Simvastatin | 2013 |
Obesity and oxidative stress: a direct link to CVD?
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; F2-Isoprostanes; Female; Humans; Hypercholesterolemia; Interleukin-6; Liver; Male; Middle Aged; Obesity; Oxidative Stress; Risk Factors; Simvastatin | 2003 |
[Statin treatment in type 2 diabetes. Is it a must today?].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Life Style; Middle Aged; Placebos; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2003 |
About the pleiotropic effects of statins in human.
Topics: Albuminuria; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Comments on the MRC/BHF Heart Protection Study.
Topics: Anticholesteremic Agents; Cause of Death; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Randomized Controlled Trials as Topic; Research Design; Simvastatin | 2003 |
Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels.
Topics: Adult; Apolipoproteins B; Cholesterol Esters; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diet Therapy; Exercise Therapy; Exudates and Transudates; Fatal Outcome; Fluorescein Angiography; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunoenzyme Techniques; Laser Coagulation; Lipids; Male; Middle Aged; Plasmapheresis; Retinal Vessels; Simvastatin | 2003 |
Role of simvastatin as an immunomodulator in type 2 diabetes.
Topics: Adjuvants, Immunologic; Aged; Antigen-Antibody Complex; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Lipoproteins; Male; Middle Aged; Osmolar Concentration; Simvastatin; Time Factors | 2004 |
Role of simvastatin as an immunomodulator in type 2 diabetes: response to Lopes-Virella et al.
Topics: Adjuvants, Immunologic; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl CoA Reductases; Simvastatin | 2004 |
Simvastatin, fenofibrate, and rhabdomyolysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Rhabdomyolysis; Simvastatin | 2005 |
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Topics: Aged; Antioxidants; Cholestenes; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Indoles; Male; Middle Aged; Oxidative Stress; Pravastatin; Prospective Studies; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
[Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Risk Factors; Simvastatin; Triglycerides | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).
Topics: Adult; Aged; Asian People; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Japan; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2007 |
Simvastatin improves the attenuated heart rate recovery of type 2 diabetics.
Topics: Autonomic Nervous System; Blood Pressure; Diabetes Mellitus, Type 2; Exercise Test; Female; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Lipids; Male; Middle Aged; Simvastatin | 2006 |
[Efficacy of simvastatin in elderly patients with type 2 diabetes].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Simvastatin; Treatment Outcome | 2006 |
Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Topics: Apolipoproteins E; Cholesterol; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Simvastatin; Treatment Outcome | 2007 |
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; Simvastatin | 2008 |
Did a flawed study design affect the results of the VYTAL study?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin | 2007 |
Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients.
Topics: Acyl Coenzyme A; Aged; China; Deoxyribonucleases, Type II Site-Specific; Diabetes Mellitus, Type 2; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Simvastatin | 2007 |
HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.
Topics: Aged; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2008 |
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Longitudinal Studies; Male; Middle Aged; Pravastatin; Pyridines; Retrospective Studies; Scotland; Simvastatin; Treatment Outcome | 2008 |
Simvastatin-induced thrombocytopaenia: a further case and a brief on its clinical relevance.
Topics: Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Count; Simvastatin; Thrombocytopenia | 2008 |
Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice.
Topics: Adrenomedullin; Animals; Aorta; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Clonidine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Mice; Mice, Inbred ICR; Nitrates; Nitrites; Nitroprusside; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Simvastatin; Vasodilation; Vasodilator Agents | 2008 |
Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Electrophysiology; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Simvastatin; Time Factors | 2008 |
High retinol/retinol-binding protein ratio in noninsulin-dependent diabetes mellitus.
Topics: Anticholesteremic Agents; Antioxidants; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; beta Carotene; Blood Glucose; Carotenoids; Cholesterol; Diabetes Mellitus, Type 2; Diterpenes; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Retinol-Binding Proteins; Retinyl Esters; Sex Characteristics; Simvastatin; Triglycerides; Vitamin A | 1995 |
Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors; Simvastatin | 1995 |
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
[Use and effect of simvastin in patients with type II diabetes].
Topics: Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Simvastatin influences testicular steroidogenesis in human.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypothalamo-Hypophyseal System; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Testicular Hormones; Testis; Triglycerides | 1993 |
Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
[Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus].
Topics: Albuminuria; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Tissue Plasminogen Activator; von Willebrand Factor | 1996 |
Detecting and correcting hyperlipidemia.
Topics: Algorithms; Decision Trees; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postmenopause; Simvastatin | 1998 |
Association between low-density lipoprotein composition and its metabolism in non-insulin-dependent diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycosylation; Humans; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 1999 |
A drug interaction between troglitazone and simvastatin.
Topics: Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Retrospective Studies; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Type 2 diabetic patients. Aggressive management of increased blood lipids].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Survival Rate | 2000 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Liver Cirrhosis; Myositis; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Hypercholesterolemia in high risk patients. Targeting low goal values].
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Myocardial Infarction; Simvastatin; Survival Rate | 2001 |
HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemotaxis, Leukocyte; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Biological; Myocardial Ischemia; Myocardial Reperfusion Injury; Necrosis; Neutrophils; Nitric Acid; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; RNA, Messenger; Simvastatin | 2001 |
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prevalence; Simvastatin; Triglycerides | 2002 |
Myopathy secondary to simvastatin in a type 2 diabetic patient.
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Simvastatin | 2002 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperlipoproteinemias; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Risk Factors; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Statin-induced fibrotic nonspecific interstitial pneumonia.
Topics: Adrenal Cortex Hormones; Biopsy, Needle; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypolipidemic Agents; Immunohistochemistry; Lung Diseases, Interstitial; Male; Middle Aged; Myocardial Infarction; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed | 2002 |
Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Simvastatin | 2002 |
The effect of simvastatin on diabetic dyslipidemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Male; Middle Aged; Prognosis; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
[Diabetes mellitus, hypercholesterolemia, and therapeutic prospects with simvastatin. General considerations and personal contribution].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |